Accuray (ARAY) Competitors

Intuitive Surgical has a net margin of 28.15% compared to Accuray's net margin of -8.15%. Intuitive Surgical's return on equity of 15.98% beat Accuray's return on equity.

In the previous week, Intuitive Surgical had 41 more articles in the media than Accuray. MarketBeat recorded 41 mentions for Intuitive Surgical and 0 mentions for Accuray. Intuitive Surgical's average media sentiment score of 1.17 beat Accuray's score of 0.88 indicating that Intuitive Surgical is being referred to more favorably in the media.

Intuitive Surgical has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Accuray has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Intuitive Surgical has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 4.4% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Intuitive Surgical currently has a consensus price target of $581.91, indicating a potential upside of 28.92%. Accuray has a consensus price target of $2.00, indicating a potential upside of 334.03%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than Intuitive Surgical.

Abbott Laboratories has a net margin of 13.90% compared to Accuray's net margin of -8.15%. Abbott Laboratories' return on equity of 17.62% beat Accuray's return on equity.

In the previous week, Abbott Laboratories had 34 more articles in the media than Accuray. MarketBeat recorded 34 mentions for Abbott Laboratories and 0 mentions for Accuray. Abbott Laboratories' average media sentiment score of 1.12 beat Accuray's score of 0.88 indicating that Abbott Laboratories is being referred to more favorably in the media.

Abbott Laboratories has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Abbott Laboratories has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 4.4% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abbott Laboratories currently has a consensus price target of $119.43, suggesting a potential upside of 37.00%. Accuray has a consensus price target of $2.00, suggesting a potential upside of 334.03%. Given Accuray's higher probable upside, analysts clearly believe Accuray is more favorable than Abbott Laboratories.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Comparatively, 4.4% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Stryker has a net margin of 13.20% compared to Accuray's net margin of -8.15%. Stryker's return on equity of 23.42% beat Accuray's return on equity.

In the previous week, Stryker had 56 more articles in the media than Accuray. MarketBeat recorded 56 mentions for Stryker and 0 mentions for Accuray. Accuray's average media sentiment score of 0.88 beat Stryker's score of 0.26 indicating that Accuray is being referred to more favorably in the news media.

Stryker has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Stryker currently has a consensus price target of $395.48, suggesting a potential upside of 33.88%. Accuray has a consensus price target of $2.00, suggesting a potential upside of 334.03%. Given Accuray's higher probable upside, analysts clearly believe Accuray is more favorable than Stryker.

Stryker has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

64.1% of Accuray shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 4.4% of Accuray shares are held by company insiders. Comparatively, 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Medtronic has a net margin of 13.00% compared to Accuray's net margin of -8.15%. Medtronic's return on equity of 14.82% beat Accuray's return on equity.

In the previous week, Medtronic had 39 more articles in the media than Accuray. MarketBeat recorded 39 mentions for Medtronic and 0 mentions for Accuray. Medtronic's average media sentiment score of 1.05 beat Accuray's score of 0.88 indicating that Medtronic is being referred to more favorably in the news media.

Accuray has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

Accuray presently has a consensus price target of $2.00, suggesting a potential upside of 334.03%. Medtronic has a consensus price target of $107.80, suggesting a potential upside of 38.61%. Given Accuray's higher probable upside, equities research analysts clearly believe Accuray is more favorable than Medtronic.

Medtronic has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.